Delivery Order SPE2DB24D2205-SPE2DB25FEHBA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $36,245.57 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order was placed under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular emphasis on...
- The Defense Logistics Agency awarded a delivery order totaling $40,340.72 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,548.16 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX. The order was placed to...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $24,643.14 to supply BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure and completion date of September 10, 2025. This non-set-aside, competitively awarded contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The place of performance is the company's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This competitive award carries a ceiling value of $66,334.24 under a firm fixed-price contract type with an ultimate completion date of September 9, 2025. The award was not designated as a set-aside contract, reflecting open competition among qualified vendors. AmerisourceBergen,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $19,036.48 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. The contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, was structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. Performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $74,049.50 firm fixed price delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with an ultimate completion date of September 15, 2025. This competitive award, issued on September 12, 2025, carries no set-aside designation and represents a continuation of the company's role as a critical pharmaceutical supplier to federal medical procurement needs. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $97,762.11 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30, with a firm fixed price structure and an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $1 billion and...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEHBADelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at approximately $122.8K, was competitively awarded without a set-aside designation and is scheduled for completion by September 4, 2025. The award was made on September 3, 2025, and represents the fulfillment of critical pharmaceutical inventory needs for federal medical procurement. This delivery order operates under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 million global pharmaceutical support vehicle active through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare systems worldwide. AmerisourceBergen's extensive federal contract portfolio with DLA demonstrates its established capability to meet competitive procurement requirements for brand-name and generic medications across multiple therapeutic domains, supporting customers including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $122.8k | 9/3/25 |